C.H. Boehringer Sohn AG & Co. KG, commonly referred to as Boehringer, is a prominent player in the pharmaceutical and animal health industries, headquartered in Germany. Founded in 1885, the company has established itself as a leader in research-driven healthcare solutions, focusing on innovative products for both human and veterinary medicine. With a strong presence in Europe, North America, and Asia, Boehringer is renowned for its commitment to advancing health through science. The company offers a diverse range of core products, including prescription medications and vaccines, distinguished by their quality and efficacy. Boehringer's dedication to research and development has led to significant milestones, solidifying its market position as a trusted name in the industry.
How does C.H. Boehringer Sohn AG & Co. KG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
C.H. Boehringer Sohn AG & Co. KG's score of 17 is lower than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, C.H. Boehringer Sohn AG & Co. KG reported no specific carbon emissions data, indicating a lack of disclosed Scope 1, 2, or 3 emissions figures. The company has not set any reduction targets or climate pledges, which suggests a need for further commitment to climate action. In 2022, the company reported CO2 emissions of approximately 0.00021 kg CO2e per unit of revenue, with total revenue of about 25.8 billion USD. This translates to a minimal carbon footprint relative to its financial performance, but specific total emissions figures remain undisclosed. C.H. Boehringer Sohn AG & Co. KG does not inherit emissions data from a parent company, and there are no cascading targets from any corporate family relationships. The absence of detailed emissions reporting highlights an opportunity for the company to enhance its transparency and accountability regarding climate commitments.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
C.H. Boehringer Sohn AG & Co. KG has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

